Success Metrics

Clinical Success Rate
83.3%

Based on 15 completed trials

Completion Rate
83%(15/18)
Active Trials
3(12%)
Results Posted
73%(11 trials)
Terminated
3(12%)

Phase Distribution

Ph phase_2
7
28%
Ph phase_4
9
36%
Ph phase_1
3
12%
Ph phase_3
2
8%

Phase Distribution

3

Early Stage

7

Mid Stage

11

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
3(14.3%)
Phase 2Efficacy & side effects
7(33.3%)
Phase 3Large-scale testing
2(9.5%)
Phase 4Post-market surveillance
9(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

15 of 18 finished

Non-Completion Rate

16.7%

3 ended early

Currently Active

3

trials recruiting

Total Trials

25

all time

Status Distribution
Active(3)
Completed(15)
Terminated(3)
Other(4)

Detailed Status

Completed15
unknown4
Recruiting3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
25
Active
3
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (14.3%)
Phase 27 (33.3%)
Phase 32 (9.5%)
Phase 49 (42.9%)

Trials by Status

recruiting312%
completed1560%
unknown416%
terminated312%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT07225842Phase 4

The Bridging Antiplatelet Therapy With Cangrelor 2 Study

Recruiting
NCT04667078Phase 3

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

Recruiting
NCT04790032

Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)

Completed
NCT02733341Phase 4

The Effect of IV Cangrelor and Oral Ticagrelor Study

Completed
NCT03551964Phase 4

Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction

Completed
NCT06792643Phase 2

Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO

Recruiting
NCT04668144Phase 4

Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

Completed
NCT03048019

Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention

Terminated
NCT04634162Phase 4

PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

Completed
NCT02765633Phase 1

Cangrelor Neonatal PK/PD and Safety Study

Completed
NCT05505591

Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry

Unknown
NCT03102723Phase 2

Platelet Inhibition to Target Reperfusion Injury

Unknown
NCT03247738Phase 4

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

Completed
NCT04138641

Dutch Cangrelor Registry

Completed
NCT03043274Phase 4

Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size

Terminated
NCT01979445Phase 2

Cangrelor to Clopidogrel or Prasugrel Transition Study

Completed
NCT02978040Phase 4

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Completed
NCT03862651Phase 2

Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)

Unknown
NCT03273075Phase 4

Add-on Cangrelor in STEMI-triggered Cardiac Arrest

Unknown
NCT01852019Phase 2

Cangrelor Prasugrel Transition Study

Completed

Drug Details

Intervention Type
DRUG
Total Trials
25